Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

(2016) A. Albertsson-Lindblad et al.   BLOOD

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

(2016) Christian W. Eskelund et al.   BRITISH JOURNAL OF HAEMATOLOGY

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

(2016) Olivier Hermine et al.   LANCET

Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

(2015) Brian G. Till et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

(2015) Dai Chihara et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

(2015) Tadeusz Robak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

(2014) J. E. Chang et al.   BLOOD

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

(2013) Andre Goy et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

(2012) Michael Wang et al.   LANCET ONCOLOGY

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

(2011) T. E. Witzig et al.   ANNALS OF ONCOLOGY

Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

(2011) Francesco Merli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non-Hodgkin Lymphoma

(2011) J. Gerecitano et al.   CLINICAL CANCER RESEARCH

Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

(2010) Jorge E. Romaguera et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

(2010) Jia Ruan et al.   JOURNAL OF CLINICAL ONCOLOGY

Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine

(2009) Mar Garcia et al.   CANCER

Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD

(2008) J. J. Shah et al.   BLOOD